BNR
Burning Rock Biotech Ltd.
NASDAQ · Healthcare · Medical - Diagnostics & Research · CN
$14.71
+8.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 500.8M | 539.6M | 515.8M | 537.4M | 563.2M |
| Cost of Revenue | 127.4M | 136.7M | 153.4M | 174.2M | 183.2M |
| Gross Profit | 373.3M | 402.9M | 362.4M | 363.2M | 380.0M |
| Operating Expenses | |||||
| R&D Expense | 135.2M | 166.5M | 232.3M | 347.0M | 421.9M |
| SG&A Expense | 303.2M | 291.3M | 452.5M | 685.5M | 938.6M |
| General & Admin Expense | 128.9M | 126.1M | 261.6M | 437.8M | 568.3M |
| Selling & Marketing Expense | 174.2M | 165.2M | 190.9M | 247.7M | 370.3M |
| Other Expenses | 7.00 | — | 35.1M | — | — |
| Total Operating Expenses | 438.4M | 457.8M | 720.0M | 1.0B | 1.4B |
| Cost and Expenses | 565.8M | 594.4M | 873.4M | 1.2B | 1.5B |
| Operating Income (EBIT) | (65.0M) | (54.8M) | (357.6M) | (669.3M) | (980.4M) |
| Non-Operating | |||||
| Interest Income | 5.9M | 8.1M | 12.2M | 18.0M | 9.5M |
| Interest Expense | 60.0K | 30.0K | — | — | — |
| Net Interest Income | 5.8M | 8.0M | 12.2M | 18.0M | 9.5M |
| Other Non-Op Income/Expense | (1.4M) | 1.1M | 16.8M | 18.0M | 11.2M |
| Non-Operating Income (excl Interest) | 1.2M | (1.1M) | (35.1M) | (18.0M) | (11.2M) |
| EBT (Pre-Tax Income) | (66.4M) | (53.8M) | (340.7M) | (651.3M) | (969.2M) |
| Income Tax Expense | 1.6M | 1.6M | 5.9M | 2.4M | 2.0M |
| Bottom Line | |||||
| Net Income | (68.0M) | (55.3M) | (346.6M) | (653.7M) | (971.2M) |
| Earnings from Cont. Ops | (68.0M) | (55.3M) | (346.6M) | (653.7M) | (971.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (68.0M) | (55.3M) | (346.6M) | (653.7M) | (971.2M) |
| Per Share | |||||
| Basic EPS | ($64.30) | ($49.60) | ($33.67) | ($63.84) | ($93.47) |
| Diluted EPS | ($64.30) | ($49.60) | ($33.67) | ($63.84) | ($93.47) |
| Revenue Per Share | $461.11 | $500.29 | $50.11 | $52.49 | $54.20 |
| Shares | |||||
| Basic Shares Outstanding | 1.1M | 1.1M | 10.3M | 10.2M | 10.4M |
| Diluted Shares Outstanding | 1.1M | 1.1M | 10.3M | 10.2M | 10.4M |
| Profitability Metrics | |||||
| EBITDA | (42.2M) | (32.0M) | (270.2M) | (517.9M) | (845.2M) |
| D&A | 24.0M | 21.8M | 52.2M | 133.4M | 124.1M |
| EBIT | (66.3M) | (53.8M) | (322.4M) | (651.3M) | (969.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026